GW Pharmaceuticals PLC- (NASDAQ:GWPH) has been assigned a $208.00 price objective by Cantor Fitzgerald in a research note issued on Monday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price would suggest a potential upside of 74.19% from the company’s current price.
Several other research firms have also weighed in on GWPH. Maxim Group set a $135.00 price target on GW Pharmaceuticals PLC- and gave the company a “buy” rating in a research report on Monday, August 7th. Goldman Sachs Group reissued a “neutral” rating and set a $124.00 price target on shares of GW Pharmaceuticals PLC- in a research report on Friday, October 6th. Bank of America dropped their price target on GW Pharmaceuticals PLC- from $160.00 to $158.00 and set a “buy” rating on the stock in a research report on Tuesday, November 14th. ValuEngine raised GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Finally, Evercore ISI assumed coverage on GW Pharmaceuticals PLC- in a research report on Wednesday, August 16th. They set an “outperform” rating and a $154.00 price target on the stock. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. GW Pharmaceuticals PLC- has an average rating of “Buy” and an average price target of $144.55.
GW Pharmaceuticals PLC- (NASDAQ GWPH) opened at $119.41 on Monday. GW Pharmaceuticals PLC- has a 52-week low of $92.65 and a 52-week high of $136.95. The company has a quick ratio of 10.26, a current ratio of 10.39 and a debt-to-equity ratio of 0.02.
Hedge funds have recently modified their holdings of the business. IHT Wealth Management LLC increased its position in GW Pharmaceuticals PLC- by 18.0% in the 2nd quarter. IHT Wealth Management LLC now owns 656 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 100 shares during the last quarter. Advisor Group Inc. increased its position in GW Pharmaceuticals PLC- by 10.7% in the 2nd quarter. Advisor Group Inc. now owns 1,500 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 145 shares during the last quarter. BNP Paribas Arbitrage SA acquired a new position in GW Pharmaceuticals PLC- in the 2nd quarter worth about $163,000. Woodmont Investment Counsel LLC acquired a new position in GW Pharmaceuticals PLC- in the 2nd quarter worth about $201,000. Finally, Van Hulzen Asset Management LLC acquired a new position in GW Pharmaceuticals PLC- in the 3rd quarter worth about $205,000. 81.85% of the stock is currently owned by institutional investors.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.